title: Respiratory disorders and hospitalization rates during the second RSV season in preterm infants who received palivizumab prophylaxis during their first RSV season.
abstract: This prospective study evaluated the frequency and severity of respiratory symptoms during the second respiratory syncytial virus (RSV) season in an italian cohort of preterm infants (< or = 35 weeks) who had received palivizumab prophylaxis in their first year of life (October 2004-April 2005) and who had not previously been hospitalized for RSV-induced lower respiratory tract infection (LRTI). infants were evaluated at enrolment (May-September 2005), in October/November 2005 and in April 2006. The occurrence of any respiratory episode, the rate of hospitalization for respiratory-related LRTI, total length of stay in hospital, physician-documented recurrent wheezing (>or = 3 physician-documented episodes of wheezing) and use of airway medication/antibiotics were recorded during follow-up. All infants had prior palivizumab prophylaxis during their first RSV season. In the total evaluable population (n=260), 32.3% of infants experienced at least one respiratory episode, 3.8% required short hospitalization because of LRTI, 8.5% had physician-documented recurrent wheezing, and 48.8% required airway medications/antibiotics during follow-up. in this study the rate of airway morbidity, hospitalization and physician-documented recurrent wheezing during the second RSV season was low among preterm infants who had received prior palivizumab prophylaxis.
authors: Neonatal Intensive Care Unit, University of Cagliari, Cagliari, Italy.
authors: V
authors: V
authors: Fanos
authors: A
authors: A
authors: Scarcella
authors: M
authors: M
authors: Puddu
authors: F
authors: F
authors: Gallini
authors: F
authors: F
authors: Tuminelli
authors: P
authors: P
authors: Bragetti
authors: M R
authors: MR
authors: Gallina
authors: L
authors: L
authors: Quartulli
authors: N
authors: N
authors: Benincori
authors: G
authors: G
authors: Citro
authors: L Dalla
authors: LD
authors: Via
authors: G
authors: G
authors: Barera
authors: U
authors: U
authors: DI Luzio Paparatti
authors: R
authors: R
authors: Merolla
authors: G V
authors: GV
authors: Romano
authors: G
authors: G
authors: Guida
authors: M
authors: M
authors: Silvestri
authors: G A
authors: GA
authors: Rossi
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D006760:Hospitalization / Q000706:statistics & numerical data*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D008297:Male; D000069455:Palivizumab; D011446:Prospective Studies; D012135:Respiratory Sounds; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*; D012140:Respiratory Tract Diseases / Q000453:epidemiology*; D012141:Respiratory Tract Infections / Q000453:epidemiology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069455:Palivizumab